Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study.

Gray RT, Cantwell MM, Coleman HG, Loughrey MB, Bankhead P, McQuaid S, O'Neill RF, Arthur K, Bingham V, McGready C, Gavin AT, Cardwell CR, Johnston BT, James JA, Hamilton PW, Salto-Tellez M, Murray LJ.

Clin Transl Gastroenterol. 2017 Apr 27;8(4):e91. doi: 10.1038/ctg.2017.18.

2.

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S.

N Engl J Med. 2012 Oct 25;367(17):1596-606. doi: 10.1056/NEJMoa1207756.

3.

Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer.

Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van Vlierberghe RL, Lemmens VE, van Herk-Sukel MP, van Wezel T, Fodde R, Kuppen PJ, Morreau H, van de Velde CJ, Liefers GJ.

JAMA Intern Med. 2014 May;174(5):732-9. doi: 10.1001/jamainternmed.2014.511.

PMID:
24687028
4.

Aspirin use and risk of colorectal cancer according to BRAF mutation status.

Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT, Ogino S.

JAMA. 2013 Jun 26;309(24):2563-71. doi: 10.1001/jama.2013.6599.

5.

Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.

Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, Song M, Mima K, Kosumi K, Liu L, Shi Y, da Silva A, Gu M, Li W, Keum N, Zhang X, Wu K, Meyerhardt JA, Giovannucci EL, Giannakis M, Rodig SJ, Freeman GJ, Nevo D, Wang M, Chan AT, Fuchs CS, Nishihara R, Ogino S.

J Clin Oncol. 2017 Jun 1;35(16):1836-1844. doi: 10.1200/JCO.2016.70.7547. Epub 2017 Apr 13.

6.

Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.

Kosumi K, Hamada T, Zhang S, Liu L, da Silva A, Koh H, Twombly TS, Mima K, Morikawa T, Song M, Nowak JA, Nishihara R, Saltz LB, Niedzwiecki D, Ou FS, Zemla T, Mayer RJ, Baba H, Ng K, Giannakis M, Zhang X, Wu K, Giovannucci EL, Chan AT, Fuchs CS, Meyerhardt JA, Ogino S.

Eur J Cancer. 2019 Apr;111:82-93. doi: 10.1016/j.ejca.2019.01.022. Epub 2019 Mar 1.

PMID:
30826660
7.

Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.

Li P, Wu H, Zhang H, Shi Y, Xu J, Ye Y, Xia D, Yang J, Cai J, Wu Y.

Gut. 2015 Sep;64(9):1419-25. doi: 10.1136/gutjnl-2014-308260. Epub 2014 Sep 19. Review.

PMID:
25239119
8.

Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study.

Gray RT, Loughrey MB, Bankhead P, Cardwell CR, McQuaid S, O'Neill RF, Arthur K, Bingham V, McGready C, Gavin AT, James JA, Hamilton PW, Salto-Tellez M, Murray LJ, Coleman HG.

Br J Cancer. 2017 Jun 6;116(12):1652-1659. doi: 10.1038/bjc.2017.139. Epub 2017 May 18.

9.

PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.

Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J, DeCensi A.

Clin Oncol (R Coll Radiol). 2016 May;28(5):317-26. doi: 10.1016/j.clon.2015.11.008. Epub 2015 Dec 17. Review.

PMID:
26712086
10.

Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.

Murphy C, Turner N, Wong HL, Sinnathamby M, Tie J, Lee B, Desai J, Skinner I, Christie M, Hutchinson R, Lunke S, Waring P, Gibbs P, Tran B.

Intern Med J. 2017 Jan;47(1):88-98. doi: 10.1111/imj.13312.

PMID:
27800646
11.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E.

Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.

PMID:
26184520
12.

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.

Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P, Cantley LC, Giovannucci EL, Fuchs CS.

J Clin Oncol. 2009 Mar 20;27(9):1477-84. doi: 10.1200/JCO.2008.18.6544. Epub 2009 Feb 23.

13.

PTGS2 (Cyclooxygenase-2) expression and survival among colorectal cancer patients: a systematic review.

Kunzmann AT, Murray LJ, Cardwell CR, McShane CM, McMenamin UC, Cantwell MM.

Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1490-7. doi: 10.1158/1055-9965.EPI-13-0263. Epub 2013 Jun 27. Review.

14.

High PTGS2 expression in post-neoadjuvant chemotherapy-treated oesophageal adenocarcinoma is associated with improved survival: a population-based cohort study.

Spence AD, Trainor J, McMenamin Ú, Turkington RC, McQuaid S, Bingham V, James J, Salto-Tellez M, McManus DT, Johnston BT, Cardwell CR, Coleman HG.

Histopathology. 2019 Mar;74(4):587-596. doi: 10.1111/his.13786. Epub 2019 Jan 25.

PMID:
30408225
15.

Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer.

Yamauchi M, Lochhead P, Imamura Y, Kuchiba A, Liao X, Qian ZR, Nishihara R, Morikawa T, Shima K, Wu K, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT, Ogino S.

Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1142-52. doi: 10.1158/1055-9965.EPI-13-0108. Epub 2013 Apr 29.

16.

Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation.

Kothari N, Kim R, Jorissen RN, Desai J, Tie J, Wong HL, Faragher I, Jones I, Day FL, Li S, Sakthinandeswaren A, Palmieri M, Lipton L, Schell M, Teer JK, Shibata D, Yeatman T, Sieber OM, Gibbs P, Tran B.

Acta Oncol. 2015 Apr;54(4):487-92. doi: 10.3109/0284186X.2014.990158. Epub 2014 Dec 31. Erratum in: Acta Oncol. 2017 Feb;56(2):375.

17.

Aspirin use and survival after diagnosis of colorectal cancer.

Chan AT, Ogino S, Fuchs CS.

JAMA. 2009 Aug 12;302(6):649-58. doi: 10.1001/jama.2009.1112.

18.

Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort.

Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ.

Am J Gastroenterol. 2011 Jul;106(7):1340-50. doi: 10.1038/ajg.2011.38. Epub 2011 Mar 15.

19.

Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis.

Zhou Y, Simmons J, Jordan CD, Sonbol MB, Maihle N, Tang SC.

Clin Breast Cancer. 2019 May 18. pii: S1526-8209(19)30066-7. doi: 10.1016/j.clbc.2019.05.004. [Epub ahead of print]

PMID:
31262687
20.

Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD).

Fink SP, Yamauchi M, Nishihara R, Jung S, Kuchiba A, Wu K, Cho E, Giovannucci E, Fuchs CS, Ogino S, Markowitz SD, Chan AT.

Sci Transl Med. 2014 Apr 23;6(233):233re2. doi: 10.1126/scitranslmed.3008481.

Supplemental Content

Support Center